Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Mol Cancer Ther (2021) 20 (2): 238–249.

https://doi.org/10.1158/1535-7163.MCT-20-0002

Published: 05 February 2021

View article titled, AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Includes: Supplementary data

Journal Articles

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Nicolas Floc'h, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho, Paul D. Smith

Mol Cancer Ther (2020) 19 (11): 2298–2307.

https://doi.org/10.1158/1535-7163.MCT-20-0103

Published: 03 November 2020

View article titled, Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Includes: Supplementary data

Journal Articles

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

Oona Delpuech, Claire Rooney, Lorraine Mooney, Dawn Baker, Robert Shaw, Michael Dymond, Dennis Wang, Pei Zhang, Sarah Cross, Margaret Veldman-Jones, Joanne Wilson, Barry R. Davies, Jonathan R. Dry, Elaine Kilgour, Paul D. Smith

Mol Cancer Ther (2016) 15 (11): 2802–2813.

https://doi.org/10.1158/1535-7163.MCT-16-0297

Published: 01 November 2016

View article titled, Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

Includes: Supplementary data

Journal Articles

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

Chandra Bartholomeusz, Xuemei Xie, Mary Kathryn Pitner, Kimie Kondo, Ali Dadbin, Jangsoon Lee, Hitomi Saso, Paul D. Smith, Kevin N. Dalby, Naoto T. Ueno

Mol Cancer Ther (2015) 14 (12): 2773–2781.

https://doi.org/10.1158/1535-7163.MCT-15-0243

Published: 06 December 2015

View article titled, MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

Includes: Supplementary data

Journal Articles

Abstract C113: The monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 triggers MCT4-dependent lactate accumulation and blocks pyruvate-lactate exchange in human cancer cells

Mounia Beloueche-Babari, Slawomir Wantuch, Markella Koniordou, Harry G. Parkes, Vaitha Arunan, Thomas R. Eykyn, Paul D. Smith, Martin O. Leach

Mol Cancer Ther (2015) 14 (12_Supplement_2): C113.

https://doi.org/10.1158/1535-7163.TARG-15-C113

Published: 01 December 2015

View article titled, Abstract C113: The monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 triggers MCT4-dependent lactate accumulation and blocks pyruvate-lactate exchange in human cancer cells

Journal Articles

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Mol Cancer Ther (2015) 14 (1): 48–58.

https://doi.org/10.1158/1535-7163.MCT-14-0406

Published: 13 January 2015

View article titled, Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Includes: Supplementary data

Journal Articles

Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

Becky M. Bola, Amy L. Chadwick, Filippos Michopoulos, Kathryn G. Blount, Brian A. Telfer, Kaye J. Williams, Paul D. Smith, Susan E. Critchlow, Ian J. Stratford

Mol Cancer Ther (2014) 13 (12): 2805–2816.

https://doi.org/10.1158/1535-7163.MCT-13-1091

Published: 04 December 2014

View article titled, Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

Includes: Supplementary data

Journal Articles

Abstract A209: Predicting genetic drivers of MEK dependency with gene expression.

Jonathan R. Dry, Darren Hodgson, Roz Brant, Tom Liptrot, Elizabeth Harrington, Carl Barrett, Paul D. Smith

Mol Cancer Ther (2013) 12 (11_Supplement): A209.

https://doi.org/10.1158/1535-7163.TARG-13-A209

Published: 01 November 2013

View article titled, Abstract A209: Predicting genetic drivers of MEK dependency with gene expression.

Journal Articles

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Denis G. Alferez, Jonathan R. Dry, Sarah V. Holt, Susie L. Weston, Gael McWalter, Garry J. Beran, Mitch Revill, Paul D. Smith, Sylvie Guichard, Stephen R. Wedge, Phillip Hedge, Robert W. Wilkinson

Mol Cancer Ther (2011) 10 (11_Supplement): C2.

https://doi.org/10.1158/1535-7163.TARG-11-C2

Published: 12 November 2011

View article titled, Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Journal Articles

Abstract A71: Basal‐ and treatment‐induced activation of the PI3K‐AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY‐142886) in melanoma

Vashisht G. Yennu-Nanda, Wanleng Deng, Paul D. Smith, Michael A. Davies

Mol Cancer Ther (2009) 8 (12_Supplement): A71.

https://doi.org/10.1158/1535-7163.TARG-09-A71

Published: 10 December 2009

View article titled, Abstract A71: Basal‐ and treatment‐induced activation of the PI3K‐AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY‐142886) in melanoma

Journal Articles

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logie, Jennifer S. McKay, Paul Martin, Samantha Steele, Richard Jenkins, Mark Cockerill, Sue Cartlidge, Paul D. Smith

Mol Cancer Ther (2007) 6 (8): 2209–2219.

https://doi.org/10.1158/1535-7163.MCT-07-0231

Published: 15 August 2007

View article titled, AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Includes: Supplementary data

NARROW

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

Abstract C113: The monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 triggers MCT4-dependent lactate accumulation and blocks pyruvate-lactate exchange in human cancer cells

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport

Abstract A209: Predicting genetic drivers of MEK dependency with gene expression.

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Abstract A71: Basal‐ and treatment‐induced activation of the PI3K‐AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY‐142886) in melanoma

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only